Education
About Us
Working with TipRanks
Follow Us
Rezolute (RZLT)
NASDAQ:RZLT
RZLT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.22 - $6.19
Previous CloseN/A
Volume107.87K
Average Volume (3M)1.34M
Market Cap
$239.72M
Enterprise Value$248.10M
Total Cash (Recent Filing)$6.94K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.35
Next Earnings
May 20, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding60,535,423
10 Day Avg. Volume2,395,162
30 Day Avg. Volume1,338,949
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.89K
Enterprise Value/Ebitda-3.39
Forecast
1Y Price Target
$12.86Price Target Upside234.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Rezolute News
PremiumCompany Announcements
Rezolute Announces Pricing of Direct Stock Offering
PremiumCompany Announcements
Rezolute Receives Positive DMC Recommendation for Phase 3 Study
PremiumCompany Announcements
Rezolute Appoints Erik Harris to Board of Directors
PremiumCompany Announcements
Rezolute’s Strategic Advances in Rare Disease Therapies---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe clinical hold on ersodetug was lifted, which clears the path for future development of the drug.
FDA ApprovalThe FDA lifted the age restriction for U.S. patients, expanding the potential patient base for ersodetug.
Financial StabilityRZLT's cash reserve of $117.8M provides financial stability and supports operations through 2Q26.
Bears Say
Regulatory ConcernsThere are potential drawbacks if RZLT files for FDA approval without any US enrollment.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RZLT FAQ
What was Rezolute’s price range in the past 12 months?
Rezolute lowest stock price was $2.21 and its highest was $6.18 in the past 12 months.
What is Rezolute’s market cap?
Rezolute’s market cap is $239.72M.
When is Rezolute’s upcoming earnings report date?
Rezolute’s upcoming earnings report date is May 20, 2025 which is in 24 days.
How were Rezolute’s earnings last quarter?
Rezolute released its earnings results on Feb 12, 2025. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $0.03.
Is Rezolute overvalued?
According to Wall Street analysts Rezolute’s price is currently Undervalued.
Does Rezolute pay dividends?
Rezolute does not currently pay dividends.
What is Rezolute’s EPS estimate?
Rezolute’s EPS estimate is -0.24.
How many shares outstanding does Rezolute have?
Rezolute has 60,535,423 shares outstanding.
What happened to Rezolute’s price movement after its last earnings report?
Rezolute reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went down -1.029%.
Which hedge fund is a major shareholder of Rezolute?
Currently, no hedge funds are holding shares in RZLT
---
Rezolute Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.86 (234.03% Upside)
$12.86 (234.03% Upside)
Blogger Sentiment
Bullish
RZLT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
37.02%
12-Months-Change
Fundamentals
Return on Equity
-74.36%
Trailing 12-Months
Asset Growth
9.65%
Trailing 12-Months
Company Description
Rezolute
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
---
RZLT Stock 12 Month Forecast
Average Price Target
$12.86
▲(234.03% Upside)
Technical Analysis
AC Immune SA
―
Diamedica Therapeutics
―
Fulcrum Therapeutics
―
Tango Therapeutics
―
Inhibikase Therapeutics
―
Best Analysts Covering RZLT
1 Year
1 Year Success Rate
8/19 ratings generated profit
1 Year Average Return
+50.16%
reiterated a buy rating 2 months ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 42.11% of your transactions generating a profit, with an average return of +50.16% per trade.
---